Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs

Testing for IgM antibodies to Borrelia burgdorferi in Scottish patients with suspected Lyme borreliosis was introduced in 2018 to supplement the IgG testing already in situ. Results from 2018 to 2020 were assessed alongside available clinical data to evaluate the utility of IgM testing in serum. An...

Descripción completa

Detalles Bibliográficos
Autores principales: Joyner, Greg, Mavin, Sally, Milner, Rachel, Lim, Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934319/
https://www.ncbi.nlm.nih.gov/pubmed/35089441
http://dx.doi.org/10.1007/s10096-021-04366-4
_version_ 1784671822567964672
author Joyner, Greg
Mavin, Sally
Milner, Rachel
Lim, Chin
author_facet Joyner, Greg
Mavin, Sally
Milner, Rachel
Lim, Chin
author_sort Joyner, Greg
collection PubMed
description Testing for IgM antibodies to Borrelia burgdorferi in Scottish patients with suspected Lyme borreliosis was introduced in 2018 to supplement the IgG testing already in situ. Results from 2018 to 2020 were assessed alongside available clinical data to evaluate the utility of IgM testing in serum. An estimated false positive rate of 25.5% was observed with IgM immunoblot vs 80.1% for IgM chemiluminescent immunoassay (CLIA). IgM testing can aid earlier diagnoses if used within a selective two-tier testing protocol: only patients with acute onset of symptoms should be tested for IgM CLIA but confirmation by immunoblot and consideration of clinical picture is necessary.
format Online
Article
Text
id pubmed-8934319
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89343192022-04-01 Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs Joyner, Greg Mavin, Sally Milner, Rachel Lim, Chin Eur J Clin Microbiol Infect Dis Brief Report Testing for IgM antibodies to Borrelia burgdorferi in Scottish patients with suspected Lyme borreliosis was introduced in 2018 to supplement the IgG testing already in situ. Results from 2018 to 2020 were assessed alongside available clinical data to evaluate the utility of IgM testing in serum. An estimated false positive rate of 25.5% was observed with IgM immunoblot vs 80.1% for IgM chemiluminescent immunoassay (CLIA). IgM testing can aid earlier diagnoses if used within a selective two-tier testing protocol: only patients with acute onset of symptoms should be tested for IgM CLIA but confirmation by immunoblot and consideration of clinical picture is necessary. Springer Berlin Heidelberg 2022-01-28 2022 /pmc/articles/PMC8934319/ /pubmed/35089441 http://dx.doi.org/10.1007/s10096-021-04366-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Report
Joyner, Greg
Mavin, Sally
Milner, Rachel
Lim, Chin
Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
title Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
title_full Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
title_fullStr Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
title_full_unstemmed Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
title_short Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
title_sort introduction of igm testing for the diagnosis of acute lyme borreliosis: a study of the benefits, limitations and costs
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934319/
https://www.ncbi.nlm.nih.gov/pubmed/35089441
http://dx.doi.org/10.1007/s10096-021-04366-4
work_keys_str_mv AT joynergreg introductionofigmtestingforthediagnosisofacutelymeborreliosisastudyofthebenefitslimitationsandcosts
AT mavinsally introductionofigmtestingforthediagnosisofacutelymeborreliosisastudyofthebenefitslimitationsandcosts
AT milnerrachel introductionofigmtestingforthediagnosisofacutelymeborreliosisastudyofthebenefitslimitationsandcosts
AT limchin introductionofigmtestingforthediagnosisofacutelymeborreliosisastudyofthebenefitslimitationsandcosts

Ejemplares similares